2022 Annual Meeting - PRO: Oligometastatic Disease
This session reviews the various oligometastatic states, existing and upcoming data supporting radiation in appropriately selected patients, intersection of radiation with systemic therapy, and practical applications of radiation treatment delivery with a focus on stereotactic ablative radiation (SABR) techniques. After the session, providers should have increased comfort in advocating for radiation with oligometastatic patients and greater proficiency of SABR treatment planning and delivery, including any relationship with ongoing or overlapping systemic therapies.
The activity is designed to meet the interests of radiation oncologists, medical oncologists, radiation dosimetrists, radiation physicists and radiation oncology residents.
Upon completion of this activity, participants should be able to:
- Advocate to referring providers, patients and insurers about appropriate indications for radiation with oligometastatic disease.
- Assess existing SABR practice patterns in their clinic and implement planning and/or delivery recommendations to elevate patient outcomes.
Beant Gill, MD is employed at Associates in Radiation Medicine, Waldorf, MD and has no financial relationships with a commercial interest.
Kamran Ahmed, MD is employed at H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL and receives compensation/remuneration/funding from BMS, Eli Lily, Genentech.
C. Jillian Tsai, MD is employed at Memorial Sloan-Kettering Cancer Center, New York City, NY and receives compensation/remuneration/funding from Varian Medical Inc.
Christopher Hays Pope, MD is employed at CARTI Cancer Center, Conway, AR and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.